Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of Seletalisib in Healthy Subjects
NCT02207595Phase 1Completed
- Sponsor
- UCB
- Start
- Aug 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of seletalisib in Sjögren's syndrome and Activated PI3K delta syndrome (APDS) (5 cohorts), sponsored by UCB. Primary endpoint: Incidence of Adverse Events. Started Aug 2014; status: completed.
02
Drugs
seletalisib
03
Conditions
Sjögren's syndromeActivated PI3K delta syndrome (APDS)
Beyond the preview
Go deeper on NCT02207595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207595.